The Impact of a Daily Dietary Supplement on Glycemic Control in Individuals With Overweight or Obesity

NCT07837817 | Not Yet Recruiting DMC

• 1 other identifier: TBD-IRB in Progress
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

This clinical trial will evaluate the efficacy of Metabolic Master Pack over a 90-day intervention period. Sixty adults will be randomized to receive either Metabolic Master Pack or placebo. Participants will wear continuous glucose monitors throughout the study, complete repeated blood collections, undergo DEXA body composition assessments, and complete dietary records. Results will provide high-quality evidence regarding the product's effects on glucose regulation and metabolic health.

Conditions

Glycemic Control; Appetite Regulation

Keywords

glycemic control; supplement; postprandial; continuous glucose monitoring; standardized meals

Outcome Measures

Primary Outcomes (2)

• Interstitial Glucose

  continuous glucose monitoring

  Continuous glucose monitoring will take place over the course of the 90 day intervention

• Blood Biomarkers

  Insulin, Glucagon, GLP-1, Ghrelin, Leptin, and other metabolic biomarkers will be analyzed as part of an acute mixed-meal tolerance test.

  Baseline (prior to any supplementation), then on day 45 of supplementation and on day 90 of supplementation. Each blood draw will be taken in the morning after an overnight fast and again 30 and 60 minutes after a standardized meal is consumed.

Secondary Outcomes (5)

• Body Composition

  Baseline and at the end of the intervention

• Dietary Patterns

  5 dietary recalls over the 90 day intervention.

• Participant Height

  At the baseline visit

• Participant mass

  Baseline, Day 45 of intervention and day 90 of intervention

• Waist circumfrence

  Baseline and at 45 days and 90 days of intervention.

Study Arms (2)

Supplement

EXPERIMENTAL

This group receives the supplement for 90 days

Dietary Supplement: natural glycemic control supplement

Placebo

PLACEBO COMPARATOR

This group receives the placebo for 90 days

Dietary Supplement: Placebo Multivitamin

Interventions

natural glycemic control supplement DIETARY_SUPPLEMENT

This trial will test the effectiveness of these unique compounds to improve postprandial glycemic excursion. This includes both long-term and acute control.

Supplement

Placebo Multivitamin DIETARY_SUPPLEMENT

This group will receive 90 days of a multivitamin placebo.

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• BMI 25-40 kg/m²
• Ability to provide informed consent

You may not qualify if:

• Taking medications that impact metabolism
• Report sustained weight loss of \>3% in the past 3 months.
• History of metabolic/bariatric surgery.
• Females who are pregnant, have been pregnant within the past 6 months, or plan to become pregnant during the study period.
• Report a current medical condition or treatment for a medical condition that could affect body weight or contradict engagement in any aspect of the outcome measures or interventions.
• Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction or history of cardiomyopathy, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).
• Resting systolic blood pressure of \>160 mmHg or resting diastolic blood pressure of \>100 mmHg. If medicated for blood pressure control, the medication dose needs to be stable for \>6 months.

Sponsors & Collaborators

• University of South Alabama: lead
• HLTH Code, LLC: collaborator

Central Study Contacts

Landon Deru, PhD

CONTACT

251-341-3849; deru@southalabama.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Model Details: randomized, double-blind, placebo-controlled clinical trial

Study Record Dates

• First Submitted: September 9, 2026
• First Posted: September 24, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: September 24, 2026

Record last verified: 2026-09